Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

News | October 23, 2013
October 23, 2013 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to...
News | October 08, 2013
October 8, 2013 — Micell Technologies Inc. announced that a peer reviewed article discussing imaging and clinical...
abbott vascular, abbott laboratories, abbott bioresorbable stents

Abbott Bioresorbable Vascular Scaffold

News | September 20, 2013
September 20, 2013— The Mount Sinai Medical Center is participating in the nationwide Absorb III clinical trial testing...
Technology | July 12, 2013
July 12, 2013 — Micell Technologies Inc. received CE mark approval for its MiStent sirolimus-eluting absorbable polymer...
News | June 24, 2013
June 24, 2013 — Final six and 12-month results of the DIRECT first-in-man clinical study were presented by study...
Elixer bioresorbable stent
Feature | May 16, 2013
May 16, 2013 — Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve ...
bioresorbable stent, zinc stent

A prototype bioresorbable zinc stent developed by the University of Michigan.

Feature | May 16, 2013
May 15, 2013 — In 2012, more than 3 million people had stents inserted in their coronary arteries. After about six...
News | April 02, 2013
April 2, 2013 — Reva Medical Inc. announced that it has initiated patient enrollment into a clinical trial with its...
News | March 20, 2013
March 20, 2013 — Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation...
Absorb Bioresorbable Vascular Scaffold Clinical Trial Acc 2013
News | March 15, 2013
March 15, 2013 — Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular...
Biosensors BioMatrix

The LEADERS Trial showed that the Biosensors BioMatrix, a drug-eluting stent with a biodegradable abluminal polymer coating, was functionally equivalent to a regular nonbiodegradable stent.

Feature | February 04, 2013 | Kamran Zamanian, Ph.D.
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents,...
Bioresorbable Stent GlobalData Peripheral Artery Disease
News | January 30, 2013
January 30, 2013 — Coronary artery disease and peripheral artery disease are global health issues that affect millions...
Abbott Absorb bioresorbable stent
Feature | January 08, 2013
January 8, 2013 — Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States....
MiStent Micell Technologies Stents Bioresorbable Clinical Trial Study
News | November 07, 2012
November 7, 2012 — Micell Technologies Inc. announced positive data from two clinical studies of its investigational...
Feature | October 31, 2012
October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting platinum...